BIONTECH SE

BNTX

Delayed - 09/22 04:00:00 pm
67.05USD	+1.41%

Prev.	66.1200
Open	65.3800
High	67.7573
Low	63.6100
Volume	1 572 284

21h ago	BIONTECH : Berenberg maintains a Buy rating
4d ago	When will COVID-19 vaccines be generally available in the U.S.?
4d ago	Coronavirus Case Numbers Stay Elevated in Parts of Midwest -- Update
4d ago	Pfizer : BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19...

	Short Term	Mid-Term	Long Term
Trend	Neutral	Neutral	Bullish
Resistance	73,0	104	85,3
Spread/Res.	-8,2%	-36%	-21%
Spread/Supp.	16%	74%	76%
Support	57,8	38,6	38,1

Sales 2020	475 M 555 M 555 M
Net income 2020	-99,8 M -117 M -117 M
Net cash 2020	1 191 M 1 391 M 1 391 M
P/E ratio 2020	-95,6x
Yield 2020	-

Capitalization	13 640 M 15 970 M 15 940 M
EV / Sales 2020	26,2x
EV / Sales 2021	4,27x
Nbr of Employees	1 400
Free-Float	92,4%

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including...

>> Read more

Sector :

Bio Therapeutic Drugs

Calendar :

2020-11-10 Earnings Release

Trading Rating :

Investor Rating :

Mean consensus	OUTPERFORM
Number of Analysts	9
Average target price	68,12 €
Last Close Price	57,27 €
Spread / Highest target	46,7%
Spread / Average Target	18,9%
Spread / Lowest Target	-17,3%